Company intelligence / Profile preview

Lila Sciences

Cambridge, Massachusetts, United Stateslila.ai ↗

Ownership: Private
Development stage: Preclinical

Overview

Lila Sciences has demonstrated that its AI-driven Autonomous Science Platform can outperform human and existing AI benchmarks in scientific reasoning, generate optimal genetic medicine constructs superior to current therapeutics, discover hundreds of novel antibodies/peptides/binders for diverse targets, and design new materials. However, detailed clinical results are not available as the company does not advance its own drug candidates into clinical trials

Therapeutic areas: Other
Modalities: AntibodyPeptidesGenetic medicine constructs
Industry: Drug Discovery Services

Partnerships

Flagship Pioneering portfolio companies

Beyond the preview

Go deeper on Lila Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lila Sciences.

Explore the full profile